National Institute on Aging; Notice of Closed Meeting, 81554 [2015-32772]
Download as PDF
mstockstill on DSK4VPTVN1PROD with NOTICES
81554
Federal Register / Vol. 80, No. 250 / Wednesday, December 30, 2015 / Notices
Center Drive, Mail Stop 9702, Rockville,
MD 20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below, may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Title of invention: Thalidomide/
lenolidomide/pomalidomide analogs
that inhibit inflammation, angiogenesis.
Description of Technology:
Thalidomide and its close analogs
(lenalidomide and pomalidomide) are
widely used to treat a variety of
diseases, such as multiple myeloma and
other cancers, as well as the symptoms
of several inflammatory disorders.
However, thalidomide is known for its
teratogenic adverse effects when first
introduced clinically in the 1950s, and
is associated with drowsiness and
peripheral neuropathy. Hence, there is
intense interest to synthesize, identify
and develop safer analogs. Researchers
at the National Institute on Aging’s Drug
Design and Development Section
synthesized novel thalidomide analogs
that demonstrate clinical potential
without being teratogenic, as initially
evaluated in in vivo zebrafish and
chicken embryo model systems and in
cell culture. These new compounds
differentially provide potent antiangiogenesis and/or anti-inflammatory
action. The agents have potential for
development of new cancer therapies
and treatment of a number of
neurological and systemic disorders
involving chronic inflammation and
elevated TNF-alpha levels.
Potential Commercial Applications:
—Cancer therapeutics
—Inflammatory disorders such as
Crohn’s disease, sarcoidosis, graftversus-host disease, and rheumatoid
arthritis
—Neuroinflammatory disorders (acute:
Traumatic brain injury and stroke;
chronic: Parkinson’s disease,
Alzheimer’s disease, multiple
sclerosis)
Value Proposition:
—Non-teratogenic
—Potent
Development Stage:
VerDate Sep<11>2014
17:59 Dec 29, 2015
Jkt 238001
In Vitro/Discovery
Inventor(s):
Nigel H. Greig (NIA), Weiming Luo
(NIA), David Tweedie (NIA), William
Douglas Figg, Sr. (NCI), Neil Vargesson
(Univ. Aberdeen, Scotland), and
Shaunna Beedie (NCI & Univ. Aberdeen,
Scotland)
Intellectual Property:
HHS Reference No. E–208–2015/0–US–
01
U.S. Provisional Patent Application
No. 62/235, 105, filed September 30,
2015, entitled ‘‘Thalidomide/
lenolidomide/pomalidomide analogs
that inhibit inflammation, angiogenesis’’
Licensing and Collaborative/CoDevelopment Research Opportunity:
The National Institute on Aging seeks
collaborators to license or co-develop
novel thalidomide analogs that
demonstrate clinical potential without
being teratogenic.
Contact Information: Requests for
copies of the patent application or
inquiries about licensing and/or
research collaboration and codevelopment opportunities should be
sent to John D. Hewes, Ph.D., email:
john.hewes@nih.gov.
CFR Citation: 35 U.S.C. 209 and 37
CFR part 404
Dated: December 22, 2015.
Thomas M. Stackhouse,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2015–32877 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; Rodent
Tissue Bank.
PO 00000
Frm 00048
Fmt 4703
Sfmt 4703
Date: January 29, 2016.
Time: 12:30 p.m. to 2:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute on Aging,
Gateway Building, Suite 2C212, 7201
Wisconsin Avenue, Bethesda, MD 20892
(Telephone Conference Call).
Contact Person: Kimberly Firth, Ph.D.,
National Institutes of Health, National
Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda,
MD 20892, 301–402–7702 firthkm@
mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: December 23, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32772 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director; Amended Notice
of Meeting
Notice is hereby given of a correction
in the meeting notice of the Big Data to
Knowledge Multi-Council Working
Group (BD2K) that was published in the
Federal Register on Friday, December
11, 2015, 80 FRN 76996.
The date of the meeting is January 11,
2016. The time and meeting access
codes remain the same.
A portion of the meeting is open to
the public, 11 a.m. to 12:00 p.m. and is
being held by teleconference only. No
physical meeting location is provided
for any interested individuals to listen
to committee discussions. Any
individual interested in listening to the
meeting discussions must call: 1–866–
692–3158 and use Passcode 2956317 for
access to the meeting.
Dated: December 23, 2015.
Anna Snouffer,
Deputy Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32768 Filed 12–29–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Biomedical
Imaging and Bioengineering; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
E:\FR\FM\30DEN1.SGM
30DEN1
Agencies
[Federal Register Volume 80, Number 250 (Wednesday, December 30, 2015)]
[Notices]
[Page 81554]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32772]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The contract proposals and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Aging Special Emphasis
Panel; Rodent Tissue Bank.
Date: January 29, 2016.
Time: 12:30 p.m. to 2:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute on Aging, Gateway Building, Suite
2C212, 7201 Wisconsin Avenue, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Kimberly Firth, Ph.D., National Institutes of
Health, National Institute on Aging, Gateway Building, 7201
Wisconsin Avenue, Suite 2C212, Bethesda, MD 20892, 301-402-7702
firthkm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging
Research, National Institutes of Health, HHS)
Dated: December 23, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-32772 Filed 12-29-15; 8:45 am]
BILLING CODE 4140-01-P